Jiangsu Jland Biotech

What Jiangsu Jland Biotech does

Jiangsu Jland Biotech (江苏江山聚源生物技术有限公司, also known as Juyuan Biotech / 聚源生物) is a privately held Chinese synthetic biology company that specializes in industrialized production and application of recombinant functional proteins, with recombinant collagen as its anchor product. Founded in 2015 as a commercialization vehicle for recombinant collagen R&D traceable to a 2004 Nanjing University of Science and Technology project led by Prof. Yang Shulin, the company operates a four-platform technology stack spanning synthetic biology, protein intelligent design, downstream product development, and efficacy testing, with proprietary Pichia pastoris (methylotrophic yeast) eukaryotic expression at the core. Disclosed technical metrics include unit expression yields of 28-30 g/L and annual production capacity of 20 metric tons of high-purity recombinant collagen powder at its Zhejiang Zhuji facility, which the company describes as the world's largest automated recombinant collagen solid-raw-material production line.

The business operates three coordinated revenue streams. First, B2B raw material sales of single- and multi-type recombinant collagens (Types I, III, IV, V, VII, XVII), recombinant fibronectin, and elastin to cosmetics, medical device, and food brands, sold under ingredient brands such as Yuelixin (悦丽欣), Beikeli (倍可丽), Yuejiaoqian (悦娇纤), ZSS, GAF1500, and LLA. Second, full-chain OEM/ODM contract manufacturing services for cosmetics and Class II/III medical devices (the 'cosmetic-device integration' model) with annual capacity exceeding 100 million cosmetic units and 50 million medical device units. Third, proprietary finished-product brands including Kemeishi (科媄氏) and Dimaison (蒂美生) in medical aesthetics, Moranti (莫兰媞) and other functional-skincare labels, the international brand MethoVia, and pepwell™ for vegan yeast-fermented collagen in the food and nutraceutical channel. Customers include 300+ global enterprises such as Innisfree, e.l.f., COSMAX, Huaxibiotin, Fulerjie, Shanghai Jiahua, Shangmei Hanshu, Libai Gaozi, and Oshmanshi.

The company holds regulatory positions disproportionate to its size: only FDA Self-GRAS certification for recombinant collagen granted to a Chinese supplier, co-drafter of national pharmaceutical industry standard YY/T 1849-2022, six group standards, ISO 13485, ISO 22716, ISO 9001, GMPC, EFfCI, RSPO, SA8000, EcoVadis, and Halal/Vegan certifications, with 60+ domestic and international invention patents. It is headquartered in Jingjiang, Jiangsu, operates six R&D centers and four production bases across China plus a London office, exports to 40+ countries, and has completed three funding rounds (2021 Series A with Yida Capital, 2023 Series B with Qianyi Capital and Evonik, and May 2025 Series C of over CNY 100M led by SDIC Equity and Yuexiu Industrial Fund). Revenue is not publicly disclosed; based on production capacity, customer count, and headcount of 101-250, current annual revenue is best estimated in the $25M-$50M band.

Name

Jiangsu Jland Biotech

Legal name

江苏江山聚源生物技术有限公司

Website

https://jlandbiotech.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Jiangsu Jland Biotech is a Chinese synthetic biology company that produces recombinant collagen using a Pichia pastoris expression system at 20 tons/year capacity, supplying B2B raw materials, OEM/ODM manufacturing, and eight proprietary brands to cosmetics, medical-device, and functional-food manufacturers across 40+ countries.

Ownership category

akta.pro rank

Product category

Recombinant collagen ingredients and bio-manufactured functional proteins

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Food Manufacturing (311), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Food And Kindred Products (2000), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids) (CRADAOAJ)

akta.pro secondary industries

Medical & Healthcare Hygiene Disposables (Patient Wipes, Underpads) (IMAMAGAF), Plant-Based & Alternative Proteins (Packaged) (CRADAAAH)

Keywords

• Recombinant collagen
• Synthetic biology proteins
• Cosmetic raw materials
• Medical device biomaterials
• OEM contract manufacturing

Headquarters

HQ city

Nanjing

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Raw Material Sales (Recombinant Collagen Ingredients): Sale of recombinant collagen raw materials including Type I, III, V, IV, VII, XVII collagens, recombinant fibronectin, and elastin to cosmetics, medical device, and food manufacturers globally. Products sold under brands including '悦丽欣', '倍可丽', '悦娇纤', ZSS, GAF1500, LLA.
2. OEM/ODM Contract Manufacturing: One-stop full-chain OEM/ODM services covering cosmetics and medical device product development, manufacturing, and quality testing. Services include both '妆械结合' (cosmetic-medical device integration) formulations and traditional cosmetic products. Annual output exceeds 100 million cosmetic units and 50 million medical device units.
3. Proprietary Brand Products: Sale of finished products under 8 proprietary brands covering medical aesthetics (科媄氏, 蒂美生) and functional skincare/beauty (莫兰缇, 瑞兮, 荷璞, 妍姿丽家, 人源活力) segments. All brands have independent intellectual property rights.
4. Food Ingredient Sales (pepwell™): Sale of yeast-fermented vegan collagen ingredients under pepwell™ brand for internal beauty, functional foods, and sports nutrition applications. Holds FDA, HALAL, and VEGAN certifications.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Jiangsu Jland Biotech designs, produces, and sells recombinant collagen raw materials (Types I, III, IV, V, VII, XVII), recombinant fibronectin, and elastin manufactured via a Pichia pastoris eukaryotic expression system. Its commercial output spans ingredient brands sold to cosmetics, medical device, and functional food manufacturers globally, full-chain OEM/ODM contract manufacturing services for cosmetics and medical devices, and finished proprietary brands across medical aesthetics and functional skincare/nutrition segments.

Product overview

Jland Biotech (Jiangsu Jland Biotech / 江苏江山聚源生物技术有限公司) is a high-tech enterprise specializing in the industrialization and application of biomimetic recombinant proteins. The company's product portfolio spans three main categories: (1) Raw material brands — 悦丽欣® (single-type recombinant collagen), 倍可丽® (multi-collagen compound formulations including 6D collagen), 悦娇纤® (recombinant fibronectin), and BSS/GAF1500/LLA specialty collagens, plus pepwell™ for the food/nutrition market; (2) Own branded finished products — 科媄氏 and 蒂美生 for medical aesthetics and medical devices, and Moranti, 瑞兮, 荷璞, 妍姿丽家, 人源活力 for functional cosmetics, plus MethoVia internationally; (3) OEM/ODM contract manufacturing services covering cosmetics, medical devices, and functional foods through its Jiangsu Juyu Medical and Changsha Juyu Medical subsidiaries. The platform integrates full-chain capabilities from gene design and strain construction through industrial-scale production, downstream application R&D, and safety/ efficacy testing, enabling one-stop solutions from raw materials to finished products.

Differentiator

Problem solved

Functional benefit

Brands

• 科媄氏 (Kemeishi): 聚源生物集团旗下专注于医疗美容和功能性护肤领域的高端品牌，采用100%人体同源胶原蛋白，针对不同年龄群体提供全生命周期美肤再生解决方案。Medical aesthetics and premium functional skincare brand under Jland Group.
• 蒂美生 (Dimaison)
• 莫兰缇 (MolanTi)
• 瑞兮
• 荷璞
• 妍姿丽家
• 人源活力
• MethoVia
• PEPWELL™
• 悦丽欣 (Yuelixin)
• 倍可丽 (BeikeLi)
• 悦娇纤 (Yuejiaoqian)

Quantifiable outcome

• Expression yield reaches 28-30g/L, globally leading
• +4 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered core and strategic.

• Boruimeisu (博瑞美素)coreStrategic or Co-development Partner · 7 March 2025Jland Biotech and Boruimeisu co-established a Joint R&D Center (共建联合研发中心) to co-develop collagen-based beauty and care formulations, redefining the collagen beauty and care paradigm through collaborative innovation.
• Evonik (赢创)strategicStrategic or Co-development Partner · 27 February 2024Jland Biotech and Evonik established a strategic partnership, combining Jland's recombinant collagen expertise with Evonik's global specialty chemicals capabilities to drive collaborative innovation and market development in functional proteins.
• Uffis (优斐斯)coreStrategic or Co-development Partner · 25 January 2024Jland Biotech and Uffis established a Joint Innovation Laboratory (联合创新实验室) focused on high-molecular biotechnology R&D. The partnership leverages Jland's recombinant collagen materials and Uffis's application expertise to develop next-generation dermatology and medical aesthetics formulations.
• Nanjing Medical University (南京医科大学)strategicStrategic or Co-development Partner · 1 January 2024Collaborative R&D partnership for recombinant collagen medical device applications. Nanjing Medical University Affiliated Stomatological Hospital used Jland's recombinant Type I collagen in published research on wound healing and medical device development.
• Nanjing University of Science and Technology (南京理工大学)coreStrategic or Co-development Partner · 1 January 2023Long-term R&D partnership with Prof. Yang Shulin's team since 2004. Established Jiangsu Province Recombinant Collagen Engineering Research Center (2018) and Recombinant Collagen Engineering Technology Research Institute. Co-developed original Pichia pastoris engineering strains and fermentation processes.
• Oral Anti Time (杭州淘淘乐生物科技有限公司)strategicGTM or Marketing PartnerStrategic partnership for oral beauty product development and distribution. Jland provides high-quality recombinant collagen food-grade ingredients; Oral Anti Time provides its new media operation capabilities and full-channel online platform channels (Douyin, Taobao) to build popular products and empower the oral beauty market.
• Fudan University, East China Normal University, China Pharmaceutical University (复旦、华师大、中国药科大学)strategicStrategic or Co-development PartnerLong-term industry-academia-research partnerships with leading Chinese universities for recombinant protein research, talent development, and technology transfer.

Scale indicators11 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Giant Biogene (巨子生物): Hong Kong-listed (2367.HK) Chinese leader in recombinant collagen for cosmetics and medical aesthetics via its Comfy and similar brands. Most direct comparable on product (recombinant collagen) and end market (cosmetics / medical aesthetics), but with a much larger brand and consumer footprint.
• Jinbo Bio / Trautec (锦波生物): Hong Kong-listed Chinese recombinant collagen specialist focused on medical device and injectable applications. Closest comparable on underlying biology (recombinant collagen) and medical device end markets, with strong hospital and aesthetics channel presence.
• COSMAX: Korea-headquartered global cosmetics ODM/CMO giant, listed as a Jland customer and a direct comparable in the B2B cosmetics contract manufacturing value chain. Overlapping end customers (multinational beauty brands) and similar OEM/ODM go-to-market motion.
• Kolmar Korea: Korea-listed global cosmetics and health supplements ODM with substantial China operations. Comparable as a contract manufacturer serving global beauty and functional food brands, with overlapping customers and similar B2B contract manufacturing business model.

Broad incumbents

• Bloomage Biotech (华熙生物): China's hyaluronic acid giant (listed 688363.SH) now aggressively expanding into recombinant collagen and functional skincare. Comparable as a major Chinese biomaterials and ingredients platform with overlapping cosmetics and medical aesthetics customers, though HA remains the core business.
• Evonik: Global German specialty chemicals major that is both a strategic partner and repeat investor in Jland. Overlapping capabilities in specialty cosmetic ingredients, bioactive proteins, and contract manufacturing; a potential competitor as well as a channel partner for Jland's international expansion.
• Croda International: UK-listed global specialty ingredients leader serving personal care, health, and performance materials markets. Competes in the cosmetic active ingredients space that Jland targets, with broader portfolio but less specialization in recombinant collagen specifically.

Emerging players

• Geltor: US-based animal-free protein ingredient company using precision fermentation (also yeast-based) to produce collagen and elastin proteins. Direct technical analog — both use recombinant/fermentation approaches to replace animal-derived proteins for cosmetics and food — but Geltor is earlier-stage and US-based.
• Modern Meadow: US-based synthetic biology company applying precision fermentation and bio-fabrication to produce sustainable protein-based materials, including collagen-like ingredients for beauty and materials applications. Adjacent technical analog using synthetic biology for protein production.
• Perfect Day: US-based precision fermentation company producing animal-free dairy proteins. Adjacent to Jland in the broader synthetic biology / precision fermentation ingredients space — useful comparable for platform economics, capacity scaling, and B2B ingredient go-to-market dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/jiangsu-jland-biotech-co-ltd

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries7 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jiangsu Jland Biotech